Drug intelligence / Profile preview

empagliflozin + MET409

Development stage: Discontinued
Lead developer: Metacrine
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of empagliflozin, a sodium-glucose cotransport-2 (SGLT2) inhibitor, and MET409, a farnesoid X receptor (FXR) agonist. This combination was investigated in a Phase 2a clinical trial for patients with type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis (NASH). In clinical trials, the combination showed enhanced liver fat reduction compared to either agent alone.

Brand names: Jardiance (empagliflozin)

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)NHE1 (Sodium/hydrogen exchanger 1)

Beyond the preview

Go deeper on empagliflozin + MET409.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on empagliflozin + MET409.

Explore the full profile